Ulcerative Colitis Market Report 2026

Ulcerative Colitis Market Overview

• Ulcerative Colitis market size has reached to $7.87 billion in 2025 • Expected to grow to $11.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: The Rise In Healthcare Expenditure The Growth Of The Ulcerative Colitis Market Due To Increased Access To Advanced Medical Care And Therapies • Market Trend: Sanofi S.A. And Teva Pharmaceuticals Forge Strategic Partnership To Advance Tev'574 In The Treatment Of Crohn's Disease And Ulcerative Colitis • North America was the largest region in 2025.

What Is Covered Under Ulcerative Colitis Market?

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) and is categorized as an autoimmune disorder in which the immune system attacks healthy tissue of the large intestine and causes inflammation on the superficial layer of the large intestine. It includes symptoms of diarrhea, weight loss, abdominal cramping, anemia, blood or pus in bowel movements, and others. The main types of drugs for ulcerative colitis are anti-inflammatory drugs, anti-TNF biologics, immunosuppressants, calcineurin inhibitors, and others. Anti-inflammatory drugs refer to a drug or substance that reduces inflammation (redness, swelling, and pain) in the body. These are prescribed for various diseases such as ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis, with molecule types including biologics and small molecules, which can be administered orally or injectable. It is used by various end-users, including hospital pharmacies, retail pharmacies, drug stores, and others.

What Is The Ulcerative Colitis Market Growth Forecast?

The ulcerative colitis market size is expected to see strong growth in the next few years. It will grow to $11.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing development of next-generation biologics, rising focus on steroid-sparing therapies, expansion of targeted immune modulation treatments, growing integration of digital patient monitoring tools, increasing investments in ibd research and innovation. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of small molecule treatments, growing focus on personalized treatment regimens, expansion of long-term disease management strategies, enhanced emphasis on early and accurate diagnosis.

Global Ulcerative Colitis Market Segmentation

1) By Drug Type: Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types 2) By Disease Type: Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis 3) By Molecule Type: Biologics, Small Molecules 4) By Route Of Administration: Oral, Injectables 5) By End-User: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Other End-User Subsegments: 1) By Anti-Inflammatory Drugs: Aminosalicylates, Corticosteroids 2) By Anti-TNF Biologics: Infliximab, Adalimumab, Golimumab 3) By Immunosuppressant: Azathioprine, Mercaptopurine 4) By Calcineurin Inhibitors: Tacrolimus, Cyclosporine 5) By Other Drug Types: JAK Inhibitors, Monoclonal Antibodies, Other Novel Therapies

What Is The Driver Of The Ulcerative Colitis Market?

The increasing healthcare expenditure is expected to propel the growth of the ulcerative colitis market going forward. Health expenditure refers to all spending for health-related services, family planning activities, nutrition activities, and emergency help, but excludes expenses for drinking water and sanitation. Healthcare expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come at higher costs, leading to greater overall spending in healthcare. Increased healthcare spending can benefit ulcerative colitis sufferers by improving access to medical care and therapies. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, increasing healthcare expenditures are driving the growth of the ulcerative colitis industry.

Key Players In The Global Ulcerative Colitis Market

Major companies operating in the ulcerative colitis market are AbbVie Inc., AstraZeneca plc, Bausch Health Companies Inc., Eli Lilly and Co., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Allergan plc, Bayer AG, Celgene Corporation, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Genentech Inc., UCB S.A., Shire plc, Ferring Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Tillotts Pharma AG, Cosmo Pharmaceuticals

Global Ulcerative Colitis Market Trends and Insights

Major companies operating in the ulcerative colitis market are focusing on developing collaborative solutions, such as strategic co-development partnerships, to accelerate late-stage biologic development and expand global commercialization capabilities. Strategic co-development partnerships refer to agreements in which two pharmaceutical companies combine scientific resources, clinical trial expertise, and commercial infrastructure to jointly advance and market a therapeutic candidate under shared financial and operational responsibilities. For instance, in 2023, Sanofi S.A., a France-based healthcare and pharmaceutical company, introduced a strategic partnership with Teva Pharmaceuticals, a US-based subsidiary of Teva Pharmaceutical Industries Ltd., to jointly develop and commercialize TEV’574, a Phase 2b biologic candidate for Crohn’s disease and ulcerative colitis, featuring an upfront payment of €0.469 billion (USD 0.50 billion), eligibility for up to €0.94 billion (USD 1.0 billion) in developmental and commercialization milestones, and a cost- and profit-sharing model in which Sanofi leads commercialization in North America, Japan, and Asia while Teva leads in Europe, Israel, and select regions.

What Are Latest Mergers And Acquisitions In The Ulcerative Colitis Market?

In March 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired Landos Biopharma for an undisclosed amount. With this acquisition, AbbVie aimed to strengthen and diversify its immunology pipeline by adding a novel, first‑in‑class oral candidate that could expand its offerings in inflammatory and autoimmune diseases. Landos Biopharma Inc. is a US-based clinical‑stage biopharmaceutical company that provides treatments for ulcerative colitis (UC).

Regional Outlook

North America was the largest region in the ulcerative colitis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ulcerative Colitis Market?

The ulcerative colitis market consists of sales of aminosalicylates and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ulcerative Colitis Market Report 2026?

The ulcerative colitis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ulcerative colitis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.